Literature DB >> 11565671

Tumor marker expression is predictive of survival in patients with esophageal cancer.

T A Aloia1, D H Harpole, C E Reed, C Allegra, M B Moore, J E Herndon, T A D'Amico.   

Abstract

BACKGROUND: This study was designed to determine the prognostic value of immunohistochemical tumor marker expression in a population of patients with node-negative esophageal cancer treated with complete resection alone.
METHODS: Resection specimens were collected from 61 patients with node-negative T1 (n = 31), T2 (n = 14), and T3 (n = 16) esophageal cancer. A panel of 10 tumor markers was chosen for immunohistochemical analysis, based on associations with differing oncologic mechanisms: apoptosis (p53), growth regulation (transforming growth factor-alpha, epidermal growth factor receptor, and Her2-neu), angiogenesis (factor VIII), metastatic potential (CD44), platinum resistance (p-glycoprotein and metallothionein), 5-fluorouracil resistance (thymidylate synthetase), and carcinogenic detoxification (glutathione S-transferase-pi).
RESULTS: Complete resection was performed in all patients (44 adenocarcinoma, 17 squamous cell carcinoma), with no operative deaths. Multivariable analysis demonstrated a significant relationship between cancer-specific death and the following variables: low-level P-gp expression (p = 0.004), high-level expression of p53 (p = 0.04), and low-level expression of transforming growth factor-alpha (p = 0.03). In addition, the number of involved tumor markers present was strongly predictive of negative outcome (p = 0.0001).
CONCLUSIONS: This study supports the prognostic value of immunohistochemical tumor markers, specifically the expression pattern of P-gp, p53, and transforming growth factor-alpha, in patients with esophageal carcinoma treated with complete resection alone.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11565671     DOI: 10.1016/s0003-4975(01)02838-7

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  12 in total

Review 1.  Gastric cancer: an update.

Authors:  Manish A Shah
Journal:  Curr Oncol Rep       Date:  2006-05       Impact factor: 5.075

2.  Using yeast two-hybrid system to identify ECRG2 associated proteins and their possible interactions with ECRG2 gene.

Authors:  Yong-Ping Cui; Jian-Bo Wang; Xin-Yu Zhang; Mei-Xia Bi; Li-Ping Guo; Shih-Hsin Lu
Journal:  World J Gastroenterol       Date:  2003-09       Impact factor: 5.742

3.  Metallothionein expression in hepatocellular carcinoma.

Authors:  Geng-Wen Huang; Lian-Yue Yang
Journal:  World J Gastroenterol       Date:  2002-08       Impact factor: 5.742

4.  Outcomes after surgery for esophageal cancer.

Authors:  Thomas A D'Amico
Journal:  Gastrointest Cancer Res       Date:  2007-09

5.  Genetics in the pathogenesis of esophageal cancer: possible predictive and prognostic factors.

Authors:  Daniel Vallböhmer; Jan Brabender; Ralf Metzger; Arnulf H Hölscher
Journal:  J Gastrointest Surg       Date:  2009-09-12       Impact factor: 3.452

6.  Surgery for esophageal cancer.

Authors:  Thomas A D'Amico
Journal:  Gastrointest Cancer Res       Date:  2008-07

Review 7.  Biomarkers in Barrett's esophagus and esophageal adenocarcinoma: predictors of progression and prognosis.

Authors:  Chin-Ann J Ong; Pierre Lao-Sirieix; Rebecca C Fitzgerald
Journal:  World J Gastroenterol       Date:  2010-12-07       Impact factor: 5.742

Review 8.  Systematic review and meta-analysis of tumor biomarkers in predicting prognosis in esophageal cancer.

Authors:  Meilan Chen; Jizheng Huang; Zhenli Zhu; Jun Zhang; Ke Li
Journal:  BMC Cancer       Date:  2013-11-11       Impact factor: 4.430

9.  Metallothionein - immunohistochemical cancer biomarker: a meta-analysis.

Authors:  Jaromir Gumulec; Martina Raudenska; Vojtech Adam; Rene Kizek; Michal Masarik
Journal:  PLoS One       Date:  2014-01-08       Impact factor: 3.240

10.  GERD-Barrett-Adenocarcinoma: Do We Have Suitable Prognostic and Predictive Molecular Markers?

Authors:  Romana Illig; Eckhard Klieser; Tobias Kiesslich; Daniel Neureiter
Journal:  Gastroenterol Res Pract       Date:  2013-03-20       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.